Fundraising Fox

Leuko Labs

Boston, US · Founded 2017 · Delaware corporation · 3 known investors

Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.

AI & Machine LearningBiotechDigital HealthMedical Devices

Founders & leadership

Leuko Labs was founded in 2017 by Carlos Castro Gonzalez and Ian Butterworth.

CCCarlos Castro Gonzalez
Carlos Castro GonzalezinCo-Founder and CEO
IBIan Butterworth
Ian ButterworthinCofounder & CTO
PH
Paul HartunginNamed on SEC filing
AB
Aurelien BourquardinChief Data Scientist
AS
Alvaro Sanchez-FerroinChief Medical Officer

Board

ASAmy Salzhauer
Amy SalzhauerinBoard directorManaging Partner at Good Growth Capital

Investors · 3

Good Growth Capital✓ verifiedCharlestonvia Amy Salzhauer · board
Dorm RoomBrooklyn · $90K – $250K
MassVenturesWaltham · $250K – $500K

Reported raises · per SEC filings

Form D private placements

$1.2M disclosed across 1 round · 2019

▶$1.2MraisedFeb 2019 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carlos Castro GonzalezExecutive Officer, Director
  • Ian ButterworthExecutive Officer, Director
  • Amy SalzhauerDirector
  • Paul HartungDirector
Offering amount
$1.7M
Amount sold
$1.2M
First sale
Feb 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Labcorp5 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.

Companies competing with Leuko Labs for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$213.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Leuko Labs do?
Leuko develops a noninvasive white blood cell monitor to track neutropenia risk in cancer patients and others undergoing treatment. The MIT spinout builds medical device hardware and AI imaging software for oncology and hematology care.
Who founded Leuko Labs?
Leuko Labs was founded by Carlos Castro Gonzalez, Ian Butterworth in 2017.
Who are Leuko Labs's investors?
Leuko Labs's investors include Good Growth Capital, Dorm Room, MassVentures.
How much funding has Leuko Labs raised?
Leuko Labs has disclosed $1.2M raised across 1 round.
Where is Leuko Labs headquartered?
Leuko Labs is headquartered in Boston, US.